Nanoxis is a biotechnology company with extensive knowledge and experience in membrane protein research. Based on our unique LPI™ technology we offer products and services to membrane protein researchers worldwide.
Roughly 70% percent of all major drugs sold today target membrane proteins linked to diseases such as diabetes, hypertension, asthma, cancer, obesity, schizophrenia, Parkinsonís, depression and epilepsy. For two thirds of all anticipated new drugs it has been predicted that they will need to act on membrane proteins.
However, only a small fraction of all membrane proteins have yet been well characterized, for example only 10% of all GPCRs have been identified. Any progress in our ability to work with membrane proteins is therefore likely to, eventually, help people with diseases to get better treatment.
The importance as well as the difficulties to study membrane proteins is well known. New solutions are in strong demand. Nanoxis has the intention to meet that demand.